SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

03 Aug 2023 Evaluate
A decent increase of about 30.26% in the sales to Rs. 1320.21 millions was observed for the quarter ended June 2023. The sales figure stood at Rs. 1013.55 millions during the year-ago period.Net profit stood at Rs. 285.12  millions  compared to Rs. 252.50 millions in the corresponding previous quarter,high by 12.92%.OP of the company witnessed a marginal growth to 474.09 millions from 336.03 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 1320.21 1013.55 30.26 1320.21 1013.55 30.26 4609.38 5300.49 -13.04
Other Income 29.18 23.57 23.80 29.18 23.57 23.80 94.89 75.77 25.23
PBIDT 474.09 336.03 41.09 474.09 336.03 41.09 1383.87 2215.62 -37.54
Interest 8.16 5.81 40.45 8.16 5.81 40.45 30.84 41.98 -26.54
PBDT 465.93 330.22 41.10 465.93 330.22 41.10 1353.03 2173.64 -37.75
Depreciation 39.55 28.85 37.09 39.55 28.85 37.09 118.15 101.18 16.77
PBT 426.38 301.37 41.48 426.38 301.37 41.48 1234.88 2072.46 -40.41
TAX 141.26 48.87 189.05 141.26 48.87 189.05 336.30 554.35 -39.33
Deferred Tax 41.63 3.00 1287.67 41.63 3.00 1287.67 29.49 32.46 -9.15
PAT 285.12 252.50 12.92 285.12 252.50 12.92 898.58 1518.11 -40.81
Equity 160.97 160.96 0.01 160.97 160.96 0.01 160.97 160.97 0.00
PBIDTM(%) 35.91 33.15 8.31 35.91 33.15 8.31 30.02 41.80 -28.18

Supriya Lifescience Share Price

641.50 4.60 (0.72%)
15-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.60
Dr. Reddys Lab 1214.00
Cipla 1224.85
Zydus Lifesciences 931.60
Lupin 2343.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×